[The analgesic effects of tetrazolo-(5,4-a)-6-methyluracil and tetrazolo(5,4-a)-6-propyluracil].
Tetrazolo-(5,4-a)-6-METHyl-uracil (compound VMI-502) and tetrazolo (5,4-a)-6-propyl-uracil (compound VMI-510) posses a marked sedative-hypnotic and analgesic action and a slightly expressed central skeletal muscles relaxant and anticonvulsant action. The analgesic (antinociceptive) action has been demonstrated by meens of 5 algesimetric methods. The compounds depress the pain reactions in case of stimulation of the superficial as well as of the deep nociceptors, too. Its analgesic action is about 3 times more intense then the action of codeine, about 20 times more intense then the action of amidopyrin and maetamizole, and about 2 times slighter then the action of morphine. The obtained results give the possibility of excluding the so called "false positive reaction". The studied compounds potentiate the analgesic action of the morphine and amidopyrine, applied in subanalgesic dose. It is assumed that by the mechanisme of his analgesic action the compounds VMI-502 and VMI-510 probably approach the non-narcotic analgesics.
D000632:Aminopyrine / Q000008:administration & dosage / Q000627:therapeutic use; D000700:Analgesics; D000818:Animals; D001393:Azoles / Q000627:therapeutic use*; D004357:Drug Synergism; D051379:Mice; D009020:Morphine / Q000008:administration & dosage / Q000627:therapeutic use; D009269:Nalorphine / Q000008:administration & dosage / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy*; D013777:Tetrazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D014498:Uracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000700:Analgesics; D001393:Azoles; D013777:Tetrazoles; D000632:Aminopyrine; D014498:Uracil; D009020:Morphine; D009269:Nalorphine
Vurkhu analgetichnotodeistvie na tetrazolo-(5,4-a)-6-methyluracil and tetrazolo(5,4-a)-6-propyluracil